The estimated Net Worth of Amar Murugan is at least $529 Mille dollars as of 16 August 2024. Mr Murugan owns over 1,158 units of Atara Biotherapeutics Inc stock worth over $222,932 and over the last 5 years he sold ATRA stock worth over $306,092.
Mr has made over 14 trades of the Atara Biotherapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,158 units of ATRA stock worth $7,678 on 16 August 2024.
The largest trade he's ever made was selling 32,401 units of Atara Biotherapeutics Inc stock on 16 May 2024 worth over $20,089. On average, Mr trades about 5,329 units every 66 days since 2020. As of 16 August 2024 he still owns at least 26,827 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Mr Murugan stock trades at the bottom of the page.
K. Amar Murugan is the Sr. VP & Gen. Counsel at Atara Biotherapeutics Inc.
Mr Murugan is 46, he's been the Sr. VP & Gen. Counsel of Atara Biotherapeutics Inc since . There are 17 older and no younger executives at Atara Biotherapeutics Inc. The oldest executive at Atara Biotherapeutics Inc is Roy Baynes, 65, who is the Independent Director.
Amar's mailing address filed with the SEC is C/O ATARA BIOTHERAPEUTICS, INC., 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS, CA, 91320.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier e Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: